Balt to Commercialize Cerus Endovascular’s Contour Neurovascular System™ and Neqstent Coil Assisted Flow Diverter in Germany
Balt to Commercialize Cerus Endovascular’s Contour Neurovascular System™ and Neqstent Coil Assisted Flow Diverter in Germany
FREMONT, Calif. and OXFORD, United Kingdom and MONTMORENCY, France, Aug. 4, 2020 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company and AB Medica Deutschland Verwaltungs GmbH, a wholly owned subsidiary of Balt, today announced that they have entered into a strategic distribution agreement providing AB Medica with the exclusive rights to market and sell the newly CE marked Contour Neurovascular System™ and the Neqstent Coil Assisted Flow Diverter devices in Germany. Terms of the agreement were not disclosed.
“Our partnership with Balt, an internationally-recognized pioneer in the neurovascular sector, reflects the strength of our innovative product line and will provide significantly increased awareness and more rapid penetration of both the Contour Neurovascular System™ and the Neqstent device within Germany, the largest market within the European Union (EU),” stated Dr. Stephen Griffin, President of Cerus Endovascular. “Physicians in Germany have indicated their desire for greater access to our products and have, therefore, been very supportive of our decision to partner locally with AB Medica. We are excited to begin working closely together and eventually, to extending the distribution agreement into other key EU countries.”
Thomas Liebig, M.D., Professor in the Institute for Diagnostic and Interventional Neuroradiology at Ludwig-Maximillian’s Universität München (LMU) and Principal Investigator of the CERUS clinical trial of the Contour Neurovascular System™, noted, “I am delighted with the progress that Cerus has made, thus far in Germany. At LMU, we performed the first case with the System in Germany back in 2018 and have been using the device consistently since CE Mark was granted.”
“Balt has a long history of delivering innovative, life-saving devices to the hands of physicians. With this partnership with Cerus, we are happy to continue with this tradition and look forward to providing two new unique products to physicians in Germany,” said Pascal Girin, CEO of Balt.
“This partnership represents the achievement of an important milestone in our stated strategy for a controlled product roll-out in key international markets such as Germany,” stated Dr. Sam Milstein, Chairman of the Board of Cerus Endovascular.
About Cerus Endovascular
Cerus Endovascular is a privately held, commercial-stage, medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems for the treatment of acute, life-threatening neurological conditions, specifically, intracranial aneurysms. The Company’s CE Marked products, the Contour Neurovascular System™ and the Neqstent Coil Assisted Flow Diverter, expand the number and types of treatable intracranial aneurysms. For more information, please go to: www.cerusendo.com.
About Balt
Since it was established in 1977, Balt has worked with interventional physicians to develop devices to treat complex life-threatening neurovascular conditions such as ischemic strokes, aneurysms and arteriovenous malformations. A pioneer in the neurovascular field, Balt designs, manufactures and distributes the broadest portfolio of products in the neurovascular space and is now focused on expanding its geographic presence in both the USA and China. Visit Balt at https://www.balt-corp.com/.
Contacts:
Melody A. Carey
Rx Communications Group, LLC
917-322-2571
mcarey@rxir.com
Mohamed Bahri
Director of Marketing
Balt
Tel +33.1.39.34.62.19
mohamed.bahri@balt.fr
View original content:SOURCE Cerus Endovascular Ltd.
